Esther (Chengdu) biopharmaceutical Co., Ltd. (hereinafter referred to as Esther) was established in 2005. Its predecessor is Esther (Chengdu) Pharmaceutical Technology Co., Ltd., which was established in 2000. Esther (Chengdu) Pharmaceutical Technology Co., Ltd. is a wholly-owned subsidiary of astatech Inc. founded by Esther founder Guo Pengsheng in Philadelphia, USA. Esther is committed to providing global pharmaceutical companies with customized R & D and production of small molecular pharmaceutical intermediates, customized R & D (CRO), (cdmo), customized production (CMO) and API process development (CMC) and chemical process safety assessment service. Located in Chengdu, the beautiful land of abundance, Esther has 7500 square meters of R & D laboratory and kilogram laboratory. The company has nearly 340 employees, including more than 200 scientific research teams, including 18 doctors. After nearly 20 years of development, Esther has provided thousands of customers with advanced intermediates for preclinical, phase I, phase II, phase III and listed new drug APIs, and new advanced intermediates for tens of thousands of new drug R & D; It has a production system from small-scale test, pilot test to industrialized scale mass production; It has established a sound process technology R & D system for API intermediates and special chemicals, quality management system with ISO9001 and ichq7 as the core, ISO14001 international environmental management certification system, OHSAS18001 occupational health management system and GB / t29490-2013 intellectual property management system. Esther has applied for 127 patents, including 98 invention patents and 72 authorized patents. Esther has more than 1000 global end customers, including the top 30 global pharmaceutical companies, distributed in Europe, America, Canada, Japan, South Korea, India, China and other countries. In order to provide long-term and stable cdmo services to customers, Esther has set up offices in the United States and India, and has multiple production bases in China: Sichuan Guang'an production base, Sichuan Yibin production base and Chongqing Changshou production base. It is planned to be officially put into use in 2022. Esther has been rated as high-tech enterprise, postdoctoral innovation practice base, academician (expert) innovation workstation and Sichuan enterprise technology center, and won the top innovation and entrepreneurship team of Sichuan high-level talent introduction thousand talents program.